Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC

Phase 1

Conditions: EGFR Gene Mutation

Interventions: Drug: YH25448

First Posted Date: 2017-02-08

Last Posted Date: 2021-08-11

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 230

Registration Number: NCT03046992

Locations: 🇰🇷
The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of
🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of

and more 13 locations

Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain

Phase 3

Completed

Conditions: Peripheral Neuropathic Pain

Interventions: Drug: YHD1119
Drug: Lyrica

First Posted Date: 2016-12-07

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 371

Registration Number: NCT02985216

Locations: 🇰🇷
Yong Chul Kim, Seoul, Korea, Republic of

A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

Phase 4

Terminated

Conditions: Metabolic Syndrome

Interventions: Drug: Telmisartan 40mg, 80 mg
Drug: Telmisartan 40mg + Rosuvastatin 20mg
Drug: Rosuvastatin 20mg
Drug: Telmisartan 80mg + Rosuvastatin 20mg

First Posted Date: 2016-11-18

Last Posted Date: 2019-04-12

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 55

Registration Number: NCT02968160

Locations: 🇰🇷
Dongguk University Medical Center, Ilsan, Korea, Republic of

A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin

Phase 1

Completed

Conditions: Hypertension
Hyperlipidemia

Interventions: Drug: Twynsta 80/5mg
Drug: Crestor 20mg

First Posted Date: 2016-11-01

Last Posted Date: 2017-02-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 60

Registration Number: NCT02951962

Locations: 🇰🇷
Chonbuk National University Hospital, Chunju, Korea, Republic of

A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea

Phase 1

Terminated

Conditions: Otitis Media
Otorrhea

Interventions: Drug: piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%
Drug: piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%
Drug: piperacillin 2% + tazobactam 0.25%
Drug: piperacillin 8% + tazobactam 1.0%
Drug: piperacillin 4% + tazobactam 0.5%

First Posted Date: 2016-06-29

Last Posted Date: 2022-01-13

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 135

Registration Number: NCT02817347

Locations: 🇰🇷
Chonnam National Universitiy Hospital, Gwangju, Chonnam, Korea, Republic of

A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin

Phase 1

Completed

Conditions: Peripheral Nueropathy Pain

Interventions: Drug: YHD1119
Drug: Lyrica

First Posted Date: 2016-05-26

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 32

Registration Number: NCT02783183

PK and Food Effect of Pregabalin Study After Dosing in Healthy Male Volunteers

Phase 1

Completed

Conditions: Peripheral Neuropathy Pain

Interventions: Drug: Lyrica
Drug: YHD1119

First Posted Date: 2016-05-26

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 64

Registration Number: NCT02783638

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

A Clinical Trial of YH23537 in Patients With Knee Osteoarthritis

Phase 2

Completed

Conditions: Knee Osteoarthritis

Interventions: Drug: YH23537
Drug: YH23537 placebo
Drug: Celecoxib

First Posted Date: 2016-05-03

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 456

Registration Number: NCT02759198

Locations: 🇰🇷
KyungHee University Medical Center, Seoul, Korea, Republic of

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: telmisartan/amlodipine 40/5mg
Drug: YH22162 40/5/12.5 mg
Drug: YH22162 80/5/25 mg
Drug: telmisartan/amlodipine 80/5mg
Drug: telmisartan/amlodipine 40/5mg placebo
Drug: YH22162 40/5/12.5 mg placebo
Drug: telmisartan/amlodipine 80/5mg placebo
Drug: YH22162 80/5/25 mg placebo

First Posted Date: 2015-12-02

Last Posted Date: 2024-11-12

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 381

Registration Number: NCT02620163

Locations: 🇰🇷
Yuhan, Seoul, Korea, Republic of

PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin

Phase 1

Terminated

Conditions: Hypertension
Hyperlipidemia

Interventions: Drug: Crestor 20mg
Drug: Twynsta 80/10mg
Drug: YH22189

First Posted Date: 2015-11-18

Last Posted Date: 2017-02-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 123

Registration Number: NCT02608242

Locations: 🇰🇷
Chonbuk National University Hospital, Chunju, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy